文章核心观点 - 公司第二季度收入同比增长13%,达到7660万美元 [2] - 公司GAAP营业利润为280万美元,非GAAP营业利润为730万美元,同比增长21% [2] - 公司预计2024年全年收入将在3.05-3.25亿美元之间,同比增长18% [4] - 公司预计2024年GAAP营业利润将在1500-1900万美元之间,调整后EBITDA将在4000-4400万美元之间,同比增长15% [4] - 公司宣布将收购Stellar Blu,这将使公司成为电子扫描天线(ESA)航空互联网市场的领导者 [7][8] 财务数据总结 收入 - 第二季度收入7660万美元,同比增长13% [2] - 上半年收入15.27亿美元,同比增长20.6% [64] - 卫星网络业务收入5.06亿美元,同比增长24.2% [63] - 综合解决方案业务收入1.30亿美元,同比增长2.1% [63] - 网络基础设施和服务业务收入1.31亿美元,同比减少7.8% [63] 利润 - 第二季度GAAP营业利润280万美元,同比下降48.7% [2] - 第二季度非GAAP营业利润730万美元,同比增长19.7% [2] - 第二季度GAAP净利润130万美元,同比下降69.9% [2] - 第二季度非GAAP净利润560万美元,同比增长13.2% [2] - 上半年GAAP净利润630万美元,同比下降36.7% [52] - 上半年非GAAP净利润1160万美元,同比增长31.8% [56] 其他财务数据 - 第二季度调整后EBITDA1010万美元,同比增长10.0% [60] - 上半年调整后EBITDA1943万美元,同比增长10.6% [60] - 截至2024年6月30日,现金及现金等价物9.37亿美元 [67][88]

Sapiens enables process modernization, speed to market, and expansion of Continental General's TPA services ROCHELLE PARK, N.J., Aug. 7, 2024 /PRNewswire/ -- Sapiens International Corporation, (NASDAQ: SPNS) (TASE: SPNS) ("Sapiens"), a leading global provider of software solutions for the insurance industry, today announced that Continental General Insurance Company (together with its affiliates, "Continental General"), a life, accident, and health insurance company, has selected Sapiens as a technology par ...

文章核心观点 - 公司在第二季度取得了强劲的业绩表现,实现了创纪录的净利润和超过10%的ROE [3][7] - 公司在各个业务板块都实现了持续增长,客户数量和交易规模均大幅增加 [8] - 公司CEO表示公司的业务模式和执行力使其在增长和盈利能力方面处于独特的地位 [4][5][6] 财务亮点 - 总营收同比增长24%,达到24亿雷亚尔 [7] - 创纪录的净利润2.23亿雷亚尔,税前利润2.98亿雷亚尔 [7] - ROE达到10.4%,连续第六个季度提升,首次达到两位数 [7] 运营亮点 - 客户总数超过3300万,活跃客户占比55.3% [8] - 交易总额达2900亿雷亚尔,同比增长47% [8] - 高净值客户数达330万,为更高参与度的客户群体 [8]

Assets Under Management Now Approximately $1 Trillion $68 Billion of Capital Raised in the Quarter Annualized FRE and DE Grew 11% and 12% to $2.5 Billion and $2.4 Billion BROOKFIELD, NEWS, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Brookfield Asset Management Ltd. (NYSE:BAM, TSX:BAM) today announced financial results for the quarter ended June 30, 2024. Connor Teskey, President of Brookfield Asset Management stated, "We had another strong quarter, which included $68 billion of capital raised. There is strong momentu ...

文章核心观点 - 公司正在加快推进AXPAXLI在湿性AMD的两项III期临床试验SOL-1和SOL-R的进度 [3][4] - SOL-R试验已获FDA确认为公司的第二个注册性试验 [4] - 公司在非增殖性糖尿病视网膜病变(NPDR)领域的HELIOS I期试验数据也取得了积极进展 [4][5] - 公司2024年第二季度总收入为1640万美元,同比增长8.3% [7] - 公司预计2024年DEXTENZA全年总收入将达6200万-6700万美元 [7] - 公司2024年第二季度净亏损为4380万美元 [11] - 公司2024年6月30日现金余额为4.597亿美元,预计可支持运营至2028年 [6] 根据目录分类总结 临床试验进展 - 公司正在加快推进AXPAXLI在湿性AMD的两项III期临床试验SOL-1和SOL-R的进度 [3][4] - SOL-R试验已获FDA确认为公司的第二个注册性试验 [4] - 公司在NPDR领域的HELIOS I期试验数据也取得了积极进展 [4][5] 财务数据 - 公司2024年第二季度总收入为1640万美元,同比增长8.3% [7] - 公司预计2024年DEXTENZA全年总收入将达6200万-6700万美元 [7] - 公司2024年第二季度净亏损为4380万美元 [11] - 公司2024年6月30日现金余额为4.597亿美元,预计可支持运营至2028年 [6]

KING OF PRUSSIA, Pa., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) ("Vertex" or the "Company"), a global provider of tax technology solutions, today announced the acquisition of ecosio, a leading B2B integration provider specializing in electronic data interchange (EDI) and e-invoicing. The closing is pending customary Austrian regulatory approval. The acquisition advances a shared vision to accelerate global commerce and deliver a single, scalable platform for automating business transacti ...

Year-to-date consolidated earnings reflect strength of core utility operationsConfirming consolidated earnings guidance of $2.36 to $2.56 per diluted shareContinued investment in system improved reliability during recent heat wave SPOKANE, Wash., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Avista Corp. (NYSE:AVA) today announced financial results for the second quarter of 2024. Net income and earnings per diluted share for the second quarter and year-to-date 2024 compared to the same periods in 2023 are presented in ...

MINNEAPOLIS, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the second quarter 2024 after the market closes on Wednesday, August 14, 2024. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Webcast and Conference Call Information To participate in ...

NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "YmAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced its management team will participate in the following upcoming investor conferences: Wedbush PacGrow Healthcare Conference Date: Tuesday, August 13, 2024 Location: New York, NY Format: Investo ...

PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced its intention to offer, subject to market and other conditions, $250,000,000 aggregate principal amount of convertible senior notes due 2029 (the "notes") in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). ANI also expects to grant the initial purchasers ...